Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Cytopathology is Scopus-indexed (Q1, CiteScore 6.1), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by John Wiley and Sons Inc.
Checked against the index lists dated .
ISSN 1934-662XVerify ISSN ↗1934-6638Verify ISSN ↗
Publisher: John Wiley and Sons Inc
Cost to publish: About US$3,000 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 107 / 428 | 75th | Q1 |
| Cancer Research | 93 / 233 | 60th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2008–present, best quartile Q1, CiteScore 6.1.
Cancer Cytopathology is Q1 in Oncology (rank 107 of 428) and Q2 in Cancer Research (rank 93 of 233), by CiteScore 2025.
Cancer Cytopathology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 6.1, which places it in quartile Q1 at the 75th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.983, quartile Q2, with an H-index of 78.
The publisher lists an article processing charge of about US$3,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Cytopathology is published by John Wiley and Sons Inc. Its print ISSN is 1934-662X and its online ISSN is 1934-6638.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Cytopathology has an h-index of 86 and a 2-year mean of 1.99 citations per paper (OpenAlex). Its Scopus CiteScore is 6.1, quartile Q1. On 2-year citations it ranks #198 of 424 Scopus journals in Oncology.
Cancer Cytopathology published 101 papers in 2025; its busiest recent year was 2020 with 183. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 86 research articles (2025–2026), authors are most often from United States (56.8%), Japan (7.6%) and Italy (6.1%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.